EPIRUS Biopharmaceuticals, Inc. (EPRS) was a big mover last session, as its shares rose nearly 16% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company, as the stock is now down almost 8% in the past one-month time frame.
Over the last 30 days, this biopharmaceutical company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, suggesting more trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.
EPIRUS Biopharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked biomedical stocks include AMAG Pharmaceuticals, Inc. (AMAG), ANI Pharmaceuticals, Inc. (ANIP) and Biogen Idec Inc. (BIIB). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment